Trials / Conditions / Stargardt Disease 1

Stargardt Disease 1

12 registered clinical trials studyying Stargardt Disease 1 — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargar NCT07002398	VeonGen Therapeutics GmbH	Phase 1 / Phase 2
Active Not Recruiting	A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease NCT06388083	Belite Bio, Inc	Phase 2 / Phase 3
Recruiting	Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) NCT06445322	Ascidian Therapeutics, Inc	—
Recruiting	Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) NCT06467344	Ascidian Therapeutics, Inc	Phase 1 / Phase 2
Active Not Recruiting	Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease NCT06300476	West China Hospital	Phase 1 / Phase 2
Active Not Recruiting	Function and Imaging Assessments for G1961E-associated Stargardt Disease NCT05674058	University Hospital, Basel, Switzerland	—
Completed	Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Star NCT05244304	Belite Bio, Inc	Phase 3
Unknown	Structural and Functional Characterization of Rare Ocular Diseases NCT05258032	Barcelona Macula Foundation	—
Completed	Study of STG-001 in Subjects With Stargardt Disease NCT04489511	Stargazer Pharmaceuticals, Inc.	Phase 2
Completed	Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease NCT03297515	Ophthalmos Research and Education Institute	N/A
Unknown	Stem Cells Therapy in Degenerative Diseases of the Retina NCT03772938	Pomeranian Medical University Szczecin	Phase 1
Unknown	Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those Wi NCT04281732	Queen's University, Belfast	—